Quantcast
Last updated on April 18, 2014 at 12:27 EDT

Latest Dennis Slamon Stories

2013-06-18 12:30:42

TORONTO, June 18, 2013 /PRNewswire/ - In a media event held this morning, two of the world's most acclaimed cancer researchers, Drs. Tak Mak of the Princess Margaret Cancer Centre, and Dennis Slamon of the University of California, Los Angeles, shared news of a major breakthrough in the decade-long pursuit to develop a new class of "sharpshooter" cancer drugs. "Dr. Slamon and I are proud to stand shoulder-to-shoulder with our fellow scientists and the donors who believe in our...

2013-06-17 12:28:14

TORONTO, June 17, 2013 /CNW/ - Two of the world's most acclaimed cancer researchers, Drs. Tak Mak of the Princess Margaret Cancer Centre, and Dennis Slamon of the University of California, Los Angeles, will share news of a major research breakthrough, funded, in large part, through the generosity of donors. When: Tuesday, June 18, 2013 at 11 am sharp Where: Princess Margaret Cancer Centre 7th Floor, Research Atrium 610 University Avenue (south of...

2012-12-05 12:24:16

LOS ANGELES, Dec. 5, 2012 /PRNewswire/ -- Researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center (JCCC) reported an encouraging increase in progression-free survival (PFS, the length of time a patient is on treatment without tumor growth) for patients with breast cancer that was estrogen receptor positive (ER+), HER2-negative who were given a combination of the standard anti-estrogen treatment, letrozole, and a new experimental drug...

2011-10-06 09:54:37

Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very aggressive disease, a researcher with UCLA's Jonsson Comprehensive Cancer Center reported Wednesday. The study also found that a regimen without the drug Adriamycin, an anthracycline commonly used as a mainstay to treat breast cancer but one that, especially when paired...

2010-09-29 08:02:00

10th Anniversary Rock the Ribbon Celebration Honors Breastcancer.org and the Millions of Lives Touched by the Nonprofit Organization ARDMORE, Pa., Sept. 29 /PRNewswire-USNewswire/ -- As a grand finale to Breast Cancer Awareness Month, Grammy Award-winning singer Harry Connick Jr. will be the featured performer at Philadelphia's famed Academy of Music on Saturday, October 30, 2010 for Rock the Ribbon - the 10th anniversary celebration and benefit concert for Breastcancer.org. (Logo:...

2008-10-13 06:00:18

By Liz Szabo Barbara Bradfield has lived to see dramatic changes in breast cancer. When she was diagnosed in 1989, Bradfield's tumor -- which produced an overabundance of a protein called HER2 -- was considered especially deadly. Today, women with tumors like hers have some of the best survival rates in breast cancer. Experts say the drug that has kept Bradfield healthy for so long, Herceptin, has changed the nature of breast cancer and helped doctors better understand what causes...

2008-08-28 15:00:47

Harry Connick, Jr. will soon be seen in "Living Proof," a TV movie about an L.A. doctor's work developing the breast cancer drug Herceptin, Lifetime said. Connick Jr. is an Emmy Award-winning actor and Grammy Award-winning singer who has appeared in the films "Hope Floats" and "Memphis Belle," as well as in the TV series "Will & Grace" and the Broadway musical "The Pajama Game." The Lifetime Original Movie, "Living Proof," is based on the true story of Dr. Dennis Slamon and his efforts...

2008-08-28 12:01:02

LOS ANGELES, Aug. 28 /PRNewswire/ -- Emmy(R) and Grammy(R) Award winner Harry Connick, Jr. ("Will & Grace,""Hope Floats") stars in the Lifetime Original Movie, "Living Proof," the moving true story of Dr. Dennis Slamon, the UCLA doctor who helped develop the life saving breast cancer drug, Herceptin, and his efforts to keep the drug trials afloat and save the lives of thousands of women. (Logo: http://www.newscom.com/cgi-bin/prnh/20080804/NYM123LOGO) Academy Award(R)-winning actress...

2007-08-09 12:04:00

Michael J. Wick, Ph.D., a recognized leader in the research of new anti-cancer drugs, has been named director of preclinical research at South Texas Accelerated Research Therapeutics (START). He will join the START team on Sept. 3. Dr. Wick comes to START from the Cancer Therapy & Research Center's (CTRC) Institute for Drug Development, where he was director of preclinical research. He is a recognized expert in the testing of novel therapies in animal models of human cancer....

2007-08-08 12:09:12

Chris H. M. Takimoto, M.D., Ph.D., an internationally recognized leader in the development of new anti-cancer drugs, has been named director of pharmacology at South Texas Accelerated Research Therapeutics (START). Dr. Takimoto comes to START from the Cancer Therapy & Research Center's Institute for Drug Development, where he was pharmacology director and held the Zachry Chair of Translational Research. START, a clinical research organization focused on developing new anti-cancer...